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Volume 57, Number 5S Abstracts 99Soccluded (OMA) LEB. Variables identiﬁed on univariate
analysis (inclusion threshold P < .08) were included in
a multivariable logistic regression model to identify inde-
pendent predictors.
Results: Of 1404 LEB patients, 162 (11.5%) had MA,
89 (6.3%) with patent and 73 (5.2%) with occluded LEB.
For PMA, 21 (23.6%) had critical graft stenosis, of which
17 (81.0%) underwent revision, with mean time to revision
of 50.76 days (SD 6 55.49). Minority race (OR, 2.69;
CI, 1.28-5.66; P ¼ .0092), diabetes (OR, 4.14; CI,
1.20-14.24; P ¼ .025), lower baseline activity score (OR,
1.92; CI, 1.24-2.98; P ¼ .0036), and negative change in
3-month activity (OR, 1.61; CI, 1.22-2.13; P ¼ .0007)
were predictors for PMA, while tissue loss was not predic-
tive (OR, 2.32; CI, 0.66-8.08; P ¼ .19).
For OMA, 64 (87.7%) had critical graft stenosis but
only 35 (54.7%) underwent revision, with mean time to
revision of 76.11 days (SD 6 80.14) and mean time to
MA of 107.37 days (SD 6 103.39).
Conclusions: PMA patients had lower rates of graft
stenosis, but were revised earlier than their OMA counter-
parts. Non-graft-related factors (demographic and func-
tional activity) also inﬂuenced PMA. Further investigation
into PMA may optimize treatment decisions.
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Objectives: To evaluate long term outcomes and sac
volume (SV) shrinkage after endovascular popliteal artery
aneurysm repair (EVPAR).
Methods: A retrospective review of EVPAR cases per-
formed between January 1999 and December 2012. SV
shrinkage, long term patency, limb salvage (LS), and
survival (S) were evaluated with K-M estimates. Anatomical
characteristics and clinical presentation were evaluated for
their association with patency using multiple logistic
regression.
Results: 46 EVPAR procedures in 42 patients. Mean
age was 68 yr, 86% were male; mean SV 42 6 12 cm3.
Elective repair in 91% of cases, while 9% treated for rupture
or thrombosis; 56% were asymptomatic, 35% had claudica-
tion and 9% rest pain. Technical success was 98%. At mean
follow-up of 84 months (range, 6 to 138 months) primary,
assisted primary, and secondary patency was 63%, 68%, and
68%; LS was 96% and S 81%. Of the 13 limbs with stent
graft failure, seven required conversion, two underwent
amputation, while four remained with mild claudication.
Of those with graft occlusion, 61% (8 out of 13) of cases
occurred within the ﬁrst year of follow-up. The overall
mean difference in aneurysm SV shrinkage at 7 years was
signiﬁcant (42 6 12 cm3 vs 21 6 8 cm3; P ¼ .02). Theassociation of covering a length >20 cm and distal landing
zone between 1 and 1.5 cm from the take off of the ante-
rior tibial artery (ATA) was a negative predictor for
improved patency (OR, 3.05; 95% CI, 1.9 to 2.3; P ¼
.005).
Conclusions: EVPAR provides successful aneurysm
exclusion with acceptable long term patency, excellent LS
and S. However, close surveillance is required, particularly
within the ﬁrst postoperative year. Patients requiring
coverage >20 cm and a distal landing zone between 1
and 1.5 cm from the ATA may be at increased risk for
failure.
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Objectives: Bone marrow aspirate injections (BMA) in
the treatment of patients with critical limb ischemia (CLI)
is a potential treatment option in poor candidates for stan-
dard revascularization procedures. While clinical trials are
ongoing, there is little comparative data to assess its efﬁcacy
compared to bypass.
Methods: 19 patients with poor revascularization
options underwent BMA. Outcomes were compared to
a cohort of 42 CLI patients undergoing infrainguinal
bypass felt to be at high risk for graft failure (previous
endovascular treatment or bypass, tibial target, and tissue
loss). BMA patients underwent harvest of 120-240 mL of
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larly into the ischemic limb.
Results: BMA patients had a higher incidence of prior
smoking (90% vs 43%; P < .05) with a trend towards fewer
diabetics (47% vs 71%; P ¼ .07). In the BMA cohort, 84%
had rest pain and 79% had tissue loss. 68% had a prior
bypass or endovascular intervention. Mean follow-up was
334 days (6170). A second BMA treatment was per-
formed in 21% due to clinical deterioration. ABI improve-
ment was 0.23 (60.25). Rest pain improved in 87.5% and
completely resolved in 56%. Wound healing occurred in
67%. 3 patients went on to amputation (Freedom from
major amputation or death at 1.5 years 89% vs 59% (Fig;
P < .05).
Conclusions: Bone marrow aspirate injection therapy
is a potential option in CLI patients who are not candidates
for bypass or endovascular intervention. Limb salvage is
unexpectedly high in this population with few other
options.
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Objectives: Limited evidence exists for management
of acute ﬁnger ischemia (AFI). We evaluated anatomic
ﬁndings, procedural management, and amputation-free
survival in a cohort of patients with AFI.Fig.Methods: Patients undergoing angiography for AFI
were identiﬁed. Data were collected from medical records,
arteriograms, and patient interviews. Outcomes included
anatomic ﬁndings, utilization of thrombolysis, complica-
tions, and amputation-free survival. Descriptive statistics
and survival analysis were used to evaluate results.
Results: 35 patients (Mean age 47.7; 19 women) were
analyzed. Symptom duration was 1-28 days; seven patients
had gangrene. Mean follow-up was 16 months. Baseline
characteristics [n (%)] included: smoking [22 (65)],
connective tissue disease [11 (31)], and repetitive hand
trauma [10 (29)]. Arterial lesions were most frequently
identiﬁed distal to the wrist (n ¼ 32), including 8 ulnar/
radial aneurysms. Proximal lesions were less common (n
¼ 11). Of 23 patients treated with thrombolysis, 11
(47.8%) had interval anatomic improvement. Eleven
patients had subsequent surgical revascularization. Compli-
cations included bleeding (n ¼ 3) and pseudoaneurysm (n
¼ 1). Estimated 1- and 6-month amputation-free survival
(SE) were 0.81 (0.07) and 0.78 (0.07), with no difference
when stratiﬁed by use of thrombolysis.
Conclusions: Angiography performed for AFI
frequently identiﬁes distal occlusive disease, and selective
thrombolysis may expand revascularization options.
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Objectives: Traditionally, thoracic outlet syndrome
(TOS) has been associated with axillo-subclavian vein
stenosis without any mention of the internal jugular (IJ)
vein. However, we recently reported a high prevalence of
IJ stenosis in 109 patients with TOS in a limited study. To
conﬁrm this ﬁnding, we analyzed a bigger cohort of patients.
Methods: We retrospectively analyzed 237 consecu-
tive unique patients referred to our practice with thoracic
outlet syndrome. From April’ 08 to Dec’ 12, all patients
underwent diagnostic brachiocephalic venograms. Avg
age was 49.9 years (r:17 to 81), with 71.8% females and
28.2% male. We looked at the right and left internal jugular
veins and the right and left subclavian veins. Stenoses were
classiﬁed into high (>66%), medium (33%-66%), and low
(<33%). We also looked for presence of collaterals around
the obstructions. Venogram ﬁndings were conﬁrmed by
four investigators independently. For the purposes of this
analysis, high stenosis was considered signiﬁcant.Medium
and low stenoses were considered signiﬁcant only if there
were visible collaterals.
Results: Left internal jugular vein stenosis, left subcla-
vian vein stenosis, right internal jugular vein stenosis, and
right subclavian vein stenosis was seen in 67.5%, 57.6%,
